Sarepta Therapeutics Inc. (SRPT) announced after the bell Monday that the FDA has requested additional information from the existing eteplirsen dataset to inform a decision on the acceptability of this dataset for a New Drug Application filing under the Subpart H Accelerated Approval regulatory pathway.
Sarepta Therapeutics has gapped open sharply lower Tuesday morning and is now down 4.68 at $34.56. The stock has dropped to over a one-week low.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.